U.S., Aug. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07111507) titled 'A Study of Tarlatamab for People With Prostate Cancer' on Aug. 01.
Brief Summary: The researchers are doing this study to find out whether tarlatamab is an effective treatment for DLL3-positive prostate cancer that has spread to other parts of your body (metastasized) and has either come back after treatment (relapsed) or not responded to treatment (refractory).
Study Start Date: July 31
Study Type: INTERVENTIONAL
Condition:
Metastatic Prostate Cancer
Intervention:
DRUG: Tarlatamab
Patients receive lower dose of tarlatamab on Cycle 1 Day 1 (D1) followed by the full dose on Cycle 1 days 8, 15 and days 1 and 15 for all subsequen...